Clinical Edge Journal Scan

MRE-based shear strain mapping may preoperatively predict microvascular invasion in HCC


 

Key clinical point: Magnetic resonance elastography (MRE)-based shear strain mapping may serve as a noninvasive biomarker enabling the characterization of the tumor-liver interface and preoperative prediction of microvascular invasion (MVI) in patients with hepatocellular carcinoma (HCC).

Major finding: The positive MVI vs. negative MVI group displayed a significantly higher octahedral shear strain (OSS) percentage of low-shear-strain length (pLSL) at three evaluation frequencies (60 Hz: 75% vs. 40%, 40 Hz: 85% vs. 40%, and 30 Hz: 70% vs. 20%; all P < .01). The peritumor OSS-pLSL area under the receiver operating characteristic curve (0.73-0.90) for MVI prediction was good/excellent at all frequencies.

Study details: The data are derived from a retrospective study of 59 patients with HCC, all of whom underwent the conventional 60 Hz MRE examination; of these, 29 patients also underwent 40 and 30 Hz MRE examinations.

Disclosures: The study was funded by the National Natural Science Foundation of China, among others. The authors declared no conflict of interests.

Source: Li M et al. MR elastography-based shear strain mapping for assessment of microvascular invasion in hepatocellular carcinoma. Eur Radiol. 2022 (Feb 11). Doi: 10.1007/s00330-022-08578-w

Recommended Reading

Sorafenib plus HAIC a favorable therapeutic option for HCC with major portal vein tumor thrombosis
Federal Practitioner
Tenofovir disoproxil fumarate vs. entecavir: Curtailing the risk of chronic hepatitis B-induced HCC
Federal Practitioner
Liver resection in HCC: Robot-assisted and laparoscopic vs. open
Federal Practitioner
Old age and liver stiffness on transient elastography may predict HCC occurrence after HCV eradication
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC March 2022
Federal Practitioner
Overall survival after curative resection for HBV-related HCC is better with tenofovir vs. entecavir
Federal Practitioner
Final phase 2 results testify to the clinical advantage of TACE plus sorafenib in unresectable HCC
Federal Practitioner
LEN-TACE sequential therapy tops LEN monotherapy in unresectable HCC responsive to initial LEN treatment
Federal Practitioner
Meta-analysis underscores the need for improved HCC surveillance in NAFLD without cirrhosis
Federal Practitioner
Ramucirumab-mediated survival benefit in advanced HCC unperturbed by baseline prognostic covariates
Federal Practitioner